[IL-6 blockade].
Copyright policy )[IL-6 blockade].
Interleukin-6 (IL-6) plays an important role in the pathogenesis of rheumatoid arthritis (RA). Tocilizumab, anti-human IL-6 receptor monoclonal antibody developed in Japan, prevents IL-6 from binding to IL-6 receptor blocking IL-6 signal. The clinical and radiographic efficacy of tocilizumab has proved in many clinical studies. Tocilizumab monotherapy is superior to methotrexate, which has not proved in TNF inhibitors, although tocilizuab in combination with methotrexate is more effective than tocilizumab monotherapy in inducing remission. Hepatotoxicity and infection are adverse events to be careful about.
Clinical Trials as Topic, Interleukin-6, Remission Induction, Antibodies, Monoclonal, Humanized, Receptors, Interleukin-6, Arthritis, Rheumatoid, Methotrexate, Treatment Outcome, Drug Discovery, Humans, Drug Therapy, Combination, Molecular Targeted Therapy
Clinical Trials as Topic, Interleukin-6, Remission Induction, Antibodies, Monoclonal, Humanized, Receptors, Interleukin-6, Arthritis, Rheumatoid, Methotrexate, Treatment Outcome, Drug Discovery, Humans, Drug Therapy, Combination, Molecular Targeted Therapy
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!